Result Summaries: elacridar
| GSK Study ID |
Phase | Title | Summary (Download) |
|---|---|---|---|
| BCR10001 | Phase 1 | A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) in Combination with 2.0 mg Oral Topotecan in Cancer Patients (1 citation(s)) |  |